glp 1 compounding fda GLP-1 Compounding: When Innovation May Mean Liability FDA moves to remove GLP-1

Conclusions In this large, real-world, propensity-matched analysis of non-diabetic patients with overactive bladder, concurrent use of GLP-1 receptor agonists was associated with a lower risk of urinary retention and UTI following BTX-A treatment

, ,

Diabetologia 56:25822592 Bailey CJ, Gross JL, Pieters A, Bastien A, List JF (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

The mechanism of action of cagrilintide includes activating satiety centers in the brain, particularly hindbrain circuits, distinguishing it mechanistically from GLP-1 receptor agonists